Diabetes Core Update Special Edition - Diabetes Core Update - CGM - January 2025
Welcome to this special edition of Diabetes Core Update, where host Dr. Neil Skolnik takes a deep dive into the transformative role of continuous glucose monitoring (CGM) in diabetes care. Through engaging conversations with two leading experts, Dr. Skolnik explores the latest advancements in CGM technology, its clinical benefits, and its growing accessibility. Packed with valuable insights, this episode is an essential listen for healthcare professionals navigating the evolving landscape of diabetes management.
This episode is sponsored by Dexcom, the #1 HCP-recommended CGM brand* and creators of Dexcom G7.
Presented by:
Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
Eden Miller, DO, Founder of Diabetes Nation, a nonprofit organization, and CEO of Diabetes and Obesity Care, Bend, Oregon
Eugene Wright, MD, Medical Director of Performance Improvement, Charlotte Area Health Education Center, Charlotte, North Carolina; Consulting Associate, Department of Medicine, Duke University Medical Center, Durham, North Carolina
Select resources and studies mentioned in the podcast:
https://pro.diabeteswise.org/en/resources
https://www.aafp.org/pubs/fpm/issues/2024/0100/continuous-glucose-monitoring.pdf
Miller E, Chuang JS, Roberts GJ, Nabutovsky Y, Virdi N, Wright Jr. EE: Association of changes in A1C following continuous glucose monitoring acquisition in people with sub‐optimally treated type 2 diabetes taking GLP‐1 RA therapy. Diabetes Therapy 2024;15:2027-2038 https://doi.org/10.1007/s13300-024-01619-1
This special episode of Diabetes Core Update is sponsored by Dexcom, the #1 HCP-recommended CGM brand* and creators of Dexcom G7 (1). Dexcom G7 is a continuous glucose monitoring system, designed for patients with all types of diabetes (2). The American Diabetes Association recommends the use of CGM in people with diabetes, as CGM is clinically proven to lower A1C, reduce hyper- and hypoglycemia, and increase time in range (3).
Getting started with Dexcom G7 is easy, with only one prescription needed. Visit https://Dexcom.com/ADA for prescribing information and to sample Dexcom G7 for free.
*Based on a comparison in NPS scores across major CGM brands.
References
1. Seagrove Partners, LLC. Seagrove Partners HCP Perspectives. 2022
2. Dexcom. Dexcom G7 User Guide. 2023
3. American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes—2025. Diabetes Care 2025;48(Suppl. 1):S1–S352